20 research outputs found
Asociación entre síndrome metabólico y enfermedad nodular tiroidea en el Hospital Nacional Edgardo Rebagliati Martins en el año 2014
Introducción: Pocos son los estudios que analizan la relación entre el síndrome metabólico y la enfermedad nodular tiroidea, tema en el que existe un vacío de conocimiento. El objetivo de este estudio es determinar la asociación entre síndrome metabólico y enfermedad nodular tiroidea en un hospital de Lima, Perú. Materiales y métodos: Estudio longitudinal, prospectivo, analítico, observacional de casos y controles, realizado en el Hospital Nacional Edgardo Rebagliati Martins en Lima - Perú. Un total de 182 pacientes se separaron como casos a los pacientes en los que se encontrara por lo menos un nódulo tiroideo detectado por ultrasonografía mayor a 3 mm (n=91) y como controles a los pacientes en los cuales se excluyera la presencia del nódulo de las características descritas por la misma técnica diagnostica (n=91). Se evaluaron el nivel y la fuerza de asociación entre la presencia de síndrome metabólico y cada uno de sus componentes por separado con la presencia de enfermedad nodular tiroidea. Resultados: El análisis bivariado muestra asociación significativa entre la presencia de nódulo tiroideo y síndrome metabólico con un OR de 2.56 (IC: 95% 1.41 a 4.66, p < 0.05). Se evidenció que los niveles de HDL bajo y la glicemia basal alterada se encuentran asociadas significativamente con la presencia de nódulo tiroideo, independientemente de la presencia de síndrome metabólico con OR de 2.81 ( IC: 95% 1.54 a 5.12, p<0.05) y 2.05 (IC:95% 1.10 a 3.78, p<0.05) respectivamente. El análisis multivariado mantuvo la asociación entre nódulo tiroideo y el síndrome metabólico con un OR de 2.96 (IC: 95% 1,47 a 5,95 , p<0.05), así mismo con niveles de HDL bajo con un OR de 2.77 (IC:95 % 1,44 a 5,3, p<0.05) y con la glicemia basal alterada con un OR de 2,23 (IC:95% 1,14 a 4,34, p<0,05). Conclusiones: El Síndrome metabólico incrementa el riesgo de padecer enfermedad nodular tiroidea, específicamente la disminución de valores de HDL y la glicemia basal alterada fueron los factores en los que halló mayor asociación.Introduction: Few studies analyses the relation between metabolic syndrome and thyroid nodular disease, subject in which there is a knowledge gap. The object of this study is to determinate the association between metabolic syndrome and thyroid nodular disease in a hospital in Lima, Peru. Materials and methods: A longitudinal, prospective, analytic, observational, case - control study, was performed “Hospital Nacional Edgardo Rebagliati Martins” in Lima- Peru. A total of 182 patients were separated as cases in which at least find a thyroid nodule detected by ultrasonography greater than 3 mm ( n = 91) and controls as patients in whom the presence of the node with the characteristics described was excluded by the same technique (n=91). The level and strength of association was evaluated between the presence of metabolic syndrome and each of its components by itself with the presence of thyroid nodular was evaluated. Results: Bivariate analysis shows significant association between the presence of thyroid nodule and metabolic syndrome with an OR of 2.56 (IC:95% 1.41 to 4.66, p < 0.05). Low levels of HDL and impaired fasting glucose are significant associated with the presence of thyroid nodule, independent of the presence of metabolic syndrome, with an OR of 2.81 (IC:95% 1.54 to 5.12, p<0.05) and 2.05 (IC: 95% 1.10 to 3.78, p<0.05) respectively. The multivariate analysis maintained the association between thyroid nodule and metabolic syndrome with an OR of 2.96 (IC: 95% 1,47 to 5,95 , p<0.05); like was the low levels of HDL with an OR of 2.77 ( IC: 95% 1,44 to 5,3, p<0.05) and with impaired fasting glucose with an OR of 2,23 ( IC 95% 1,14 to 4,34, p<0,05).Conclusions: Metabolic syndrome increases de risk of having thyroid nodule disease. Low HDL levels and impaired fasting glucose were the factors with more association.Tesi
Factors Associated with Anti-Tuberculosis Medication Adverse Effects: A Case-Control Study in Lima, Peru
BACKGROUND: Long-term exposure to anti-tuberculosis medication increases risk of adverse drug reactions and toxicity. The objective of this investigation was to determine factors associated with anti-tuberculosis adverse drug reactions in Lima, Peru, with special emphasis on MDR-TB medication, HIV infection, diabetes, age and tobacco use. METHODOLOGY AND RESULTS: A case-control study was performed using information from Peruvian TB Programme. A case was defined as having reported an anti-TB adverse drug reaction during 2005-2010 with appropriate notification on clinical records. Controls were defined as not having reported a side effect, receiving anti-TB therapy during the same time that the case had appeared. Crude, and age- and sex-adjusted models were calculated using odds ratios (OR) and 95% confidence intervals (95%CI). A multivariable model was created to look for independent factors associated with side effect from anti-TB therapy. A total of 720 patients (144 cases and 576 controls) were analyzed. In our multivariable model, age, especially those over 40 years (OR = 3.93; 95%CI: 1.65-9.35), overweight/obesity (OR = 2.13; 95%CI: 1.17-3.89), anemia (OR = 2.10; IC95%: 1.13-3.92), MDR-TB medication (OR = 11.1; 95%CI: 6.29-19.6), and smoking (OR = 2.00; 95%CI: 1.03-3.87) were independently associated with adverse drug reactions. CONCLUSIONS: Old age, anemia, MDR-TB medication, overweight/obesity status, and smoking history are independent risk factors associated with anti-tuberculosis adverse drug reactions. Patients with these risk factors should be monitored during the anti-TB therapy. A comprehensive clinical history and additional medical exams, including hematocrit and HIV-ELISA, might be useful to identify these patients
Ecología de la información: de la práctica teórica a la práctica profesional
El libro Ecología de la información: de la práctica teórica a la práctica profesional tiene como objetivo dar a conocer las áreas temáticas y las perspectivas metodológicas y teóricas utilizadas por estudiantes de la Carrera de Comunicación de la Universidad Politécnica Salesiana.
Esta publicación recoge el material creado en el aula y recicla la información producida. Análisis de discursos políticos y de noticieros, temas de género, interculturalidad, transparencia, ciberactivismo, hacen parte de esta publicación.
La práctica de la investigación científica busca sembrar la inquietud en el alumnado en áreas vinculadas a lo social, cultural, político, comunicativo y de desarrollo
Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors
Purpose The primary aim of this study was to evaluate if exposure to 5-alpha-reductase inhibitors (5-ARIs) modifies the effect of MRI for the diagnosis of clinically significant Prostate Cancer (csPCa) (ISUP Gleason grade >= 2).Methods This study is a multicenter cohort study including patients undergoing prostate biopsy and MRI at 24 institutions between 2013 and 2022. Multivariable analysis predicting csPCa with an interaction term between 5-ARIs and PIRADS score was performed. Sensitivity, specificity, and negative (NPV) and positive (PPV) predictive values of MRI were compared in treated and untreated patients.Results 705 patients (9%) were treated with 5-ARIs [median age 69 years, Interquartile range (IQR): 65, 73; median PSA 6.3 ng/ml, IQR 4.0, 9.0; median prostate volume 53 ml, IQR 40, 72] and 6913 were 5-ARIs naive (age 66 years, IQR 60, 71; PSA 6.5 ng/ml, IQR 4.8, 9.0; prostate volume 50 ml, IQR 37, 65). MRI showed PIRADS 1-2, 3, 4, and 5 lesions in 141 (20%), 158 (22%), 258 (37%), and 148 (21%) patients treated with 5-ARIs, and 878 (13%), 1764 (25%), 2948 (43%), and 1323 (19%) of untreated patients (p < 0.0001). No difference was found in csPCa detection rates, but diagnosis of high-grade PCa (ISUP GG >= 3) was higher in treated patients (23% vs 19%, p = 0.013). We did not find any evidence of interaction between PIRADS score and 5-ARIs exposure in predicting csPCa. Sensitivity, specificity, PPV, and NPV of PIRADS >= 3 were 94%, 29%, 46%, and 88% in treated patients and 96%, 18%, 43%, and 88% in untreated patients, respectively.Conclusions Exposure to 5-ARIs does not affect the association of PIRADS score with csPCa. Higher rates of high-grade PCa were detected in treated patients, but most were clearly visible on MRI as PIRADS 4 and 5 lesions.Trial registration The present study was registered at ClinicalTrials.gov number: NCT05078359
Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality
Understanding the relation between Zika virus infection during pregnancy and adverse fetal, infant and child outcomes: a protocol for a systematic review and individual participant data meta-analysis of longitudinal studies of pregnant women and their infants and children
IntroductionZika virus (ZIKV) infection during pregnancy is a known cause of microcephaly and other congenital and developmental anomalies. In the absence of a ZIKV vaccine or prophylactics, principal investigators (PIs) and international leaders in ZIKV research have formed the ZIKV Individual Participant Data (IPD) Consortium to identify, collect and synthesise IPD from longitudinal studies of pregnant women that measure ZIKV infection during pregnancy and fetal, infant or child outcomes.Methods and analysisWe will identify eligible studies through the ZIKV IPD Consortium membership and a systematic review and invite study PIs to participate in the IPD meta-analysis (IPD-MA). We will use the combined dataset to estimate the relative and absolute risk of congenital Zika syndrome (CZS), including microcephaly and late symptomatic congenital infections; identify and explore sources of heterogeneity in those estimates and develop and validate a risk prediction model to identify the pregnancies at the highest risk of CZS or adverse developmental outcomes. The variable accuracy of diagnostic assays and differences in exposure and outcome definitions means that included studies will have a higher level of systematic variability, a component of measurement error, than an IPD-MA of studies of an established pathogen. We will use expert testimony, existing internal and external diagnostic accuracy validation studies and laboratory external quality assessments to inform the distribution of measurement error in our models. We will apply both Bayesian and frequentist methods to directly account for these and other sources of uncertainty.Ethics and disseminationThe IPD-MA was deemed exempt from ethical review. We will convene a group of patient advocates to evaluate the ethical implications and utility of the risk stratification tool. Findings from these analyses will be shared via national and international conferences and through publication in open access, peer-reviewed journals.Trial registration numberPROSPERO International prospective register of systematic reviews (CRD42017068915).</jats:sec